Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in their interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider transactions rather than a financial performance report.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The only changes disclosed relate to the shareholdings of Sir Andrew Witty, a Director of the company.
Management Commentary and Risks
The filing details specific transactions executed on April 25, 2012, by Sir Andrew Witty:
- Transfer of 250 Ordinary Shares into an Individual Savings Account (ISA) at a price of £14.1325 per share.
- Gift of 500 Ordinary Shares to each of his two children.
The company and the involved parties were advised of these transactions on April 26, 2012, in accordance with Disclosure Rule 3.1.4R(1)(a) and (c). No other risks, contingencies, or unusual items are mentioned.
Investor Verification Points
- Verify the total number of shares held by Sir Andrew Witty following these transactions to assess his current stake.
- Confirm the market price of GSK shares on April 25, 2012, to contextualize the £14.1325 transaction price.
- Review subsequent filings for any further insider trading activity or changes in director interests.